Biogen Inc.'s stock took a hit in the pre-market trading session on Wednesday, plummeting 5.3% as the biopharmaceutical company forecasted 2025 profit below Wall Street expectations.
The company's lackluster performance is attributed to two key factors:
1. The impact of a strong U.S. dollar, which has eroded the company's overseas revenue and profit.
2. Intensifying competition for its multiple sclerosis drugs, which have faced fierce rivalry in the market.
Despite efforts by the new CEO, Christopher Viehbacher, to streamline operations and pursue acquisitions, such as the $6.5 billion takeover of Reata Pharmaceuticals in 2023, concerns remain about Biogen's ability to sustain growth. The company expects 2025 revenue to decline by a mid-single-digit percentage, excluding currency fluctuations, from 2024 levels.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。